<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Steed AL</submitter><funding>NICHD NIH HHS</funding><funding>NIDDK NIH HHS</funding><funding>NIAID NIH HHS</funding><funding>NHLBI NIH HHS</funding><funding>Crohn’s Colitis</funding><pagination>498-502</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC5753406</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>357(6350)</volume><pubmed_abstract>The microbiota is known to modulate the host response to influenza infection through as-yet-unclear mechanisms. We hypothesized that components of the microbiota exert effects through type I interferon (IFN), a hypothesis supported by analysis of influenza in a gain-of-function genetic mouse model. Here we show that a microbially associated metabolite, desaminotyrosine (DAT), protects from influenza through augmentation of type I IFN signaling and diminution of lung immunopathology. A specific human-associated gut microbe, &lt;i>Clostridium orbiscindens,&lt;/i> produced DAT and rescued antibiotic-treated influenza-infected mice. DAT protected the host by priming the amplification loop of type I IFN signaling. These findings show that specific components of the enteric microbiota have distal effe</pubmed_abstract><journal>Science (New York, N.Y.)</journal><pubmed_title>The microbial metabolite desaminotyrosine protects from influenza through type I interferon.</pubmed_title><pmcid>PMC5753406</pmcid><funding_grant_id>R01 AI111605</funding_grant_id><funding_grant_id>T32 DK007130</funding_grant_id><funding_grant_id>U19 AI070412</funding_grant_id><funding_grant_id>U19 AI070489</funding_grant_id><funding_grant_id>K12 HD000850</funding_grant_id><funding_grant_id>UH3 HL123429</funding_grant_id><funding_grant_id>award312855</funding_grant_id><funding_grant_id>P30 DK056341</funding_grant_id><funding_grant_id>R01 AI130591</funding_grant_id><pubmed_authors>Steed AL</pubmed_authors><pubmed_authors>Stappenbeck TS</pubmed_authors><pubmed_authors>Christophi GP</pubmed_authors><pubmed_authors>Esaulova E</pubmed_authors><pubmed_authors>Morales DJ</pubmed_authors><pubmed_authors>Sun L</pubmed_authors><pubmed_authors>Artyomov MN</pubmed_authors><pubmed_authors>Lenschow DJ</pubmed_authors><pubmed_authors>Holtzman MJ</pubmed_authors><pubmed_authors>Goodwin VM</pubmed_authors><pubmed_authors>Kaiko GE</pubmed_authors><pubmed_authors>Jain U</pubmed_authors><pubmed_authors>Boon ACM</pubmed_authors></additional><is_claimable>false</is_claimable><name>The microbial metabolite desaminotyrosine protects from influenza through type I interferon.</name><description>The microbiota is known to modulate the host response to influenza infection through as-yet-unclear mechanisms. We hypothesized that components of the microbiota exert effects through type I interferon (IFN), a hypothesis supported by analysis of influenza in a gain-of-function genetic mouse model. Here we show that a microbially associated metabolite, desaminotyrosine (DAT), protects from influenza through augmentation of type I IFN signaling and diminution of lung immunopathology. A specific human-associated gut microbe, &lt;i>Clostridium orbiscindens,&lt;/i> produced DAT and rescued antibiotic-treated influenza-infected mice. DAT protected the host by priming the amplification loop of type I IFN signaling. These findings show that specific components of the enteric microbiota have distal effe</description><dates><release>2017-01-01T00:00:00Z</release><publication>2017 Aug</publication><modification>2025-04-03T23:18:23.27Z</modification><creation>2019-03-27T03:06:22Z</creation></dates><accession>S-EPMC5753406</accession><cross_references><pubmed>28774928</pubmed><doi>10.1126/science.aam5336</doi></cross_references></HashMap>